These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7665720)

  • 21. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions.
    Violaris AG; Melkert R; Serruys PW
    Circulation; 1994 Nov; 90(5):2267-79. PubMed ID: 7955183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin.
    Arca M; Vega GL; Grundy SM
    JAMA; 1994 Feb; 271(6):453-9. PubMed ID: 8295321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences of regional coronary flow reserve assessed by adenosine thallium-201 scintigraphy early and six months after successful percutaneous transluminal coronary angioplasty or stent implantation.
    Versaci F; Tomai F; Nudi F; Gaspardone A; De Fazio A; Ciavolella M; Crea F; Mango L; Chiariello L; Gioffrè PA
    Am J Cardiol; 1996 Nov; 78(10):1097-102. PubMed ID: 8914870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restenosis after transluminal coronary angioplasty: a risk factor analysis.
    Gürlek A; Dağalp Z; Oral D; Omürlü K; Erol C; Akyol T; Tutar E
    J Cardiovasc Risk; 1995 Feb; 2(1):51-5. PubMed ID: 7606641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.
    Desmet W; Vrolix M; De Scheerder I; Van Lierde J; Willems JL; Piessens J
    Circulation; 1994 Jan; 89(1):385-92. PubMed ID: 8281674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Schwartz L; Bourassa MG; Lespérance J; Aldridge HE; Kazim F; Salvatori VA; Henderson M; Bonan R; David PR
    N Engl J Med; 1988 Jun; 318(26):1714-9. PubMed ID: 2967433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Normalization of lipid metabolism disturbances and clinical course after percutaneous coronary angioplasty: 6 month observation].
    Ochała A; Gabrylewicz B; Bartnik M; Garbocz P; Wycisk A; Lewicki A; Kaźmierski M; Tendera M
    Pol Arch Med Wewn; 2000 Dec; 104(6):833-41. PubMed ID: 11424662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective, randomized, and double-blind trial on the effect of fish oil on the incidence of restenosis following PTCA.
    Franzen D; Schannwell M; Oette K; Höpp HW
    Cathet Cardiovasc Diagn; 1993 Apr; 28(4):301-10. PubMed ID: 8462079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia.
    Bradford RH; Shear CL; Chremos AN; Dujovne C; Franklin FA; Hesney M; Higgins J; Langendörfer A; Pool JL; Schnaper H
    Am J Cardiol; 1990 Sep; 66(8):44B-55B. PubMed ID: 2206036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II).
    Savage MP; Goldberg S; Bove AA; Deutsch E; Vetrovec G; Macdonald RG; Bass T; Margolis JR; Whitworth HB; Taussig A
    Circulation; 1995 Dec; 92(11):3194-200. PubMed ID: 7586303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group.
    Waksman R; Kosinski AS; Klein L; Boccuzzi SJ; King SB; Ghazzal ZM; Weintraub WS
    Am J Cardiol; 1996 Jul; 78(2):221-4. PubMed ID: 8712148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty.
    Bairati I; Roy L; Meyer F
    Circulation; 1992 Mar; 85(3):950-6. PubMed ID: 1537131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
    Bestehorn HP; Rensing UF; Roskamm H; Betz P; Benesch L; Schemeitat K; Blümchen G; Claus J; Mathes P; Kappenberger L; Wieland H; Neiss A
    Eur Heart J; 1997 Feb; 18(2):226-34. PubMed ID: 9043838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study).
    Nakamura Y; Yamaoka O; Uchida K; Morigami N; Sugimoto Y; Fujita T; Inoue T; Fuchi T; Hachisuka M; Ueshima H; Shimakawa H; Kinoshita M
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):475-83. PubMed ID: 8924063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.
    Cairns JA; Gill J; Morton B; Roberts R; Gent M; Hirsh J; Holder D; Finnie K; Marquis JF; Naqvi S; Cohen E
    Circulation; 1996 Oct; 94(7):1553-60. PubMed ID: 8840843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Preventive effect of pravastatin on restenosis following coronary angioplasty: prospective randomized trial].
    Iwasaki K; Kusachi S; Hina K; Yamasaki S; Nishiyama O; Takaishi A; Kita T; Taniguchi G
    J Cardiol; 1995 Jan; 25(1):15-21. PubMed ID: 7877098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia.
    Bradford RH; Shear CL; Chremos AN; Franklin FA; Nash DT; Hurley DP; Dujovne CA; Pool JL; Schnaper H; Hesney M
    Am J Med; 1991 Jul; 91(1B):18S-24S. PubMed ID: 1867232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of exercise testing in relationship to coronary artery bypass surgery and percutaneous transluminal coronary angioplasty.
    Weiner DA; Chaitman BR
    Cardiology; 1986; 73(4-5):242-58. PubMed ID: 2944582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.